CINECA IRIS Institutional Research Information System

SABA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.384
EU - Europa 2.838
AS - Asia 2.795
SA - Sud America 458
OC - Oceania 55
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.976
CN - Cina 1.363
IT - Italia 565
SE - Svezia 380
JP - Giappone 370
SG - Singapore 323
DE - Germania 310
MX - Messico 263
FR - Francia 217
BR - Brasile 181
GB - Regno Unito 159
IE - Irlanda 158
AT - Austria 156
UA - Ucraina 147
FI - Finlandia 115
ES - Italia 109
IN - India 107
CA - Canada 104
KR - Corea 95
RU - Federazione Russa 85
PL - Polonia 83
VN - Vietnam 81
TW - Taiwan 80
ID - Indonesia 73
PE - Perù 72
CO - Colombia 70
HK - Hong Kong 63
TR - Turchia 63
BE - Belgio 56
AU - Australia 52
EC - Ecuador 51
GR - Grecia 48
TH - Thailandia 35
CL - Cile 34
NL - Olanda 33
PT - Portogallo 31
SI - Slovenia 29
CH - Svizzera 28
RO - Romania 28
AR - Argentina 27
MY - Malesia 23
IR - Iran 22
DK - Danimarca 20
IL - Israele 15
PH - Filippine 15
EG - Egitto 13
GT - Guatemala 13
CZ - Repubblica Ceca 12
VE - Venezuela 11
HU - Ungheria 10
BO - Bolivia 9
BY - Bielorussia 8
HN - Honduras 8
NO - Norvegia 8
AZ - Azerbaigian 7
BG - Bulgaria 7
MM - Myanmar 7
PA - Panama 7
PK - Pakistan 7
RS - Serbia 7
LK - Sri Lanka 6
LV - Lettonia 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
LB - Libano 5
SA - Arabia Saudita 5
SN - Senegal 5
ZA - Sudafrica 5
CR - Costa Rica 4
ET - Etiopia 4
EU - Europa 4
HR - Croazia 4
JO - Giordania 4
KZ - Kazakistan 4
MD - Moldavia 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
BF - Burkina Faso 3
CV - Capo Verde 3
GH - Ghana 3
LT - Lituania 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
CD - Congo 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
KE - Kenya 2
MA - Marocco 2
PR - Porto Rico 2
SV - El Salvador 2
TN - Tunisia 2
AL - Albania 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
IQ - Iraq 1
IS - Islanda 1
Totale 9.577
Salva come PNG Salva come JPEG
Città #
Chandler 439
Beijing 327
Ann Arbor 198
Singapore 194
Dublin 157
Vienna 140
Ashburn 122
Torino 112
Dearborn 110
Santa Clara 108
Fairfield 103
Shanghai 95
Redwood City 93
Villeurbanne 92
Tokyo 84
Wilmington 83
Nyköping 81
Woodbridge 79
Turin 78
Guangzhou 77
Houston 74
Jacksonville 74
Ottawa 59
Medford 58
Taipei 54
Princeton 53
Columbus 47
Lima 47
Cambridge 46
Pisa 44
Seattle 44
Warsaw 44
Nanjing 43
Dong Ket 39
Hangzhou 37
Wuhan 35
Brussels 34
Rome 34
Milan 33
Chongqing 32
Changsha 31
Fremont 31
Jakarta 31
Boardman 29
Helsinki 29
New York 29
Munich 28
São Paulo 28
Bogotá 26
Mexico City 26
Santiago 26
Chengdu 23
London 22
Hanoi 21
Glasgow 20
Hefei 20
Istanbul 20
Los Angeles 20
Shenyang 20
Tianjin 20
Athens 19
Boston 19
Jinan 19
Paris 19
Zhengzhou 19
Hong Kong 18
Bangkok 17
Düsseldorf 17
Guayaquil 17
Saint Petersburg 17
Kunming 16
Mexico 16
Central 15
Frankfurt am Main 15
Kuala Lumpur 15
Monterrey 15
Belo Horizonte 14
Fuzhou 14
Guadalajara 14
Hyderabad 14
Osaka 14
Nuremberg 13
San Diego 13
Valencia 13
Guatemala City 12
San Jose 12
Barcelona 11
Buenos Aires 11
Changchun 11
Madrid 11
Norwalk 11
Toronto 11
Ankara 10
Arequipa 10
Brisbane 10
Caruaru 10
Cuenca 10
Mumbai 10
Quito 10
Sydney 10
Totale 4.755
Salva come PNG Salva come JPEG
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.782
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 857
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances 459
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 445
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 272
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 241
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 183
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 182
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 174
Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications 169
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 157
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 157
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 144
Metabolic handling of an oral fat load in NAFLD patients. 140
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 139
Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma 136
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 135
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 131
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 130
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 128
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 128
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 127
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 124
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 121
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 118
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 115
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 115
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 109
INCIDENCE AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATED WITH IMPAIRED LIPID AND GLUCOSE METABOLISM ARE PREDICTED BY SREBF POLYMORPHISM. 108
Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. 108
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 107
After oral fat load NAFLD subjects and healthy controls show different serum free fatty acid trends. 105
Compositional Characteristics and Antioxidant Activity of Edible Rose Flowers and Their Effect on Phenolic Urinary Excretion 104
Serum free fatty acid composition is associated with different degrees of fibrosis. 102
SREBF-1C polymorphism affects postprandial lipid metabolism in NAFLD subjects. 102
Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease 101
Postprandial cholesterol metabolism: a clue to the impact of TM6SF2 rs58542926 variant on liver and cardiovascular disease in NAFLD? 100
LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1) POLYMORPHISM IS INDEPENDENTLY ASSOCIATED WITH LIVER HISTOLOGY IN NASH. 88
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic NAFLD patients: correlation with liver damage. 84
MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes Role of mononuclear cell activation and adipokine response to dietary fat 83
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic nafld patients: correlation with liver damage. 82
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 81
GLUCOSE HOMEOSTASIS AND POSTPRANDIAL LIPOPROTEIN METABOLISM IN NONALCOHOLIC STEATOHEPATITIS (NASH) ARE AFFECTED BY LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1) POLYMORPHISM. 77
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 69
Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression 68
Effect of phospholipid curcumin Meriva® on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial 35
Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: A systematic review 24
Analytical and clinical comparison between two different analytical methods for the measurement of circulating insulin in patients with metabolic-dysfunction associated steatotic liver disease 24
Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease 23
EFFICACIA DELLA CURCUMINA NEL TRATTAMENTO DELLA STEATOSI EPATICA NON ALCOLICA (NAFLD). EFFECT OF CURCUMIN FOR NONALCOHOLIC STEATO-EPATITIS 15
Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies 10
Totale 9.818
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.668
article - articoli 0
book - libri 0
conference - conferenze 9.571
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020215 0 0 0 0 0 0 0 0 0 108 44 63
2020/2021892 60 68 20 67 99 76 37 48 73 100 115 129
2021/20221.515 60 99 79 123 118 83 155 96 82 180 257 183
2022/20231.643 137 158 98 155 141 274 117 129 137 93 109 95
2023/20241.384 137 160 111 108 107 166 100 94 16 112 141 132
2024/20251.980 142 183 227 184 363 182 172 179 273 75 0 0
Totale 9.818